ライフサイエンスコーパス: -negative

1 vels of 35 inflammatory markers in 406 HIV-1-negative individuals.

2 ectly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected bef

3 mising imaging agent for ER-positive, HER(2)-negative breast cancer.

4 ast cancer cell line (ER-positive and HER(2)-negative) demonstrated specific uptake with a maximum in

5 For 380 SARS-CoV-2-negative pre-operative samples from patients undergoing

6 ions >= 1:16, while none of the 6 SARS-CoV-2-negative sera revealed neutralizing activity.

7 ll population were apparent only in HLA-B*57-negative patients.

8 Study 1 randomly assigned (1:1) HLA-B*5701-negative adults without hepatitis B virus co-infection t

9 nting the number of Ki-67-positive and Ki-67-negative tumor cells within a subjectively picked hot-sp

10 type-1 BrS pattern after ajmaline (ajmaline-negative); (4) 47 normal subjects; (5) 18 patients with

11 never observed in normal, RBBB, or ajmaline-negative patients.

12 neurodegeneration, 19 patients with amyloid-negative neurodegeneration, and 17 healthy controls were

13 d various strains of both Gram-positive and -negative bacteria revealed distinct binding patterns, wh

14 .5) from a discovery cohort of HLA antibody-negative, endothelial cell crossmatch-positive sera obta

15 s, while showing no activity against antigen-negative cells.

16 review, 91.1% of manual-positive/automation-negative specimens were due to expert rules that reporte

17 om the lowest concentrations in amyloid beta-negative young adults and cognitively unimpaired older a

18 P-tau217 did not change in amyloid-beta-negative participants, or in patients with mild cognitiv

19 8-100 months) and were diagnosed with biopsy-negative MMP.

20 y carbon-neutral but also potentially carbon-negative.

21 colleagues perform a genome-wide CRISPR-Cas9-negative loss-of-function screen and identify WEE1 kinas

22 ucts, we identified a memory-progenitor CD39-negative stem-like phenotype (CD39(-)CD69(-)) associated

23 months vs 19% and 1.6 months for classifier-negative patients (hazard ratio, 0.49; 95% confidence in

24 phthalmitis (2 Candida glabrata, 2 coagulase-negative Staphylococcus, 1 Streptococcus pneumoniae).

25 howed the following sensitivities (coagulase-negative staphylococci not included): Gram-positive bact

26 for the clinical observation that coagulase-negative staphylococci are a highly prominent infectious

27 ), 29 (31.5%), and 13 (14.1%) were coagulase-negative staphylococci, other gram-positive, and gram-ne

28 Culture-negative pneumonia accounted for 61% of cases and was si

29 522 influenza ED visits, N = 274 226 culture-negative pneumonia hospitalizations, and N = 113 997 cul

30 ia hospitalizations, and N = 113 997 culture-negative pneumonia ED visits included in our analyses.

31 Change in clinical management for culture-negative endophthalmitis eyes was based on worsening cli

32 For culture-negative samples, mean cost-per-positive 16S PCR result

33 artment (ED) visits for influenza or culture-negative pneumonia from 2005 to 2016.

34 htheriae by culture and Elek, 6 were culture-negative but PCR-positive for diphtheria toxin gene, 1 w

35 es were culture-positive and 26 were culture-negative.

36 ntensity levels than incubation with culture-negative samples.

37 The third pattern (TH-positive, DAT-negative, ZsGreen-negative) was found in A12-A13.

38 p.Arg138Cys) variants resulted in a dominant-negative effect.

39 ations drive pathogenesis through a dominant-negative loss-of-function mechanism in autophagy and tha

40 t the fusion protein acts through a dominant-negative mechanism to cause this fatal mitochondrial dis

41 of the Spc110 C terminus acts as a dominant-negative mutant that titrates endogenous Spc110 from the

42 n in AML patients (R882H) encodes a dominant-negative protein that reduces methyltransferase activity

43 paB kinase inhibitor BAY11-7085 and dominant-negative mutant IkappaBalphaM inhibited NF-kappaB activi

44 me (AD-HIES) is typically caused by dominant-negative (DN) STAT3 mutations.

45 Klp64D cargo domain also results in dominant-negative wing notching.

46 cal neurons using overexpression of dominant-negative forms of several transcription factors, includi

47 are disrupted by the expression of dominant-negative mutants of Rab5 and Rab11.

48 ed vesicle traffic similarly to the dominant-negative truncated protein SYP121(DeltaC), which blocks

49 es to differentiate from CD4(-)CD8(-) double-negative (DN) cell to CD4(+)CD8(+) double-positive (DP)

50 identify CD4(-)CD8(-)TCRalphabeta(+), double-negative (DN) T cells, in mouse secondary lymphoid organ

51 001) compared to recipients who remained DSA-negative over the first-year posttransplant.

52 r reactivity to autoantigens compared to DSA-negative (P < .0001) and AMR patients with DSA and PRA >

53 ubiquitination in both EBV-infected and EBV-negative cells.

54 w that SOX11 confers distinct features to ER-negative DCIS.com breast cancer cells, leading to popula

55 False-negative rates were obtained for the DL risk score, age-

56 False-negative rates were slightly lower for DBT (0.6 per 1000

57 Eleven (84.6%) false-negative tears underwent follow-up within days based on

58 , resulting in high false-positive and false-negative calls.

59 likelihoods of both false-positive and false-negative inferences.

60 oints were the detection rate (DR) and false-negative rate (FNR) of TLNB and TAD after NST.

61 the false-positive rate was <=20% and false-negative rate was <=35%.

62 ed morbidity, fewer false-positive and false-negative results, lower-cost, and higher analytical freq

63 cal implications of false-positive and false-negative results.

64 All (16/16) CryptoPS false-negative results were obtained for samples with IMMY tit

65 his probability, resulting in delayed (false-negative) declarations.

66 d on high-risk characteristics, and no false-negative tears progressed to detachment at follow-up.

67 been misinterpreted, reviews causes of false-negative and false-positive results, and provides strate

68 t could help exclude false-positive or false-negative results.

69 The pitfalls involve potential false-negative results due to blurring or missing lesions or f

70 on rate (CDR) per 1000 women screened, false-negative rate per 1000 women screened, positive predicti

71 e-existing PVD at the time of surgery (false-negative results).

72 diagnostic test results (ie, suspected false-negative test results) compared with a representative po

73 Among those who are genotype-negative, >40% normalize their ECG after detraining, but

74 Gram-negative bacteremia is a common infection that results i

75 Gram-negative bacteria and their complex cell envelope, which

76 Gram-negative bacteria have evolved numerous pathways to secr

77 Gram-negative bacteria, mitochondria, and chloroplasts all po

78 Gram-negative bacterial lipoproteins are triacylated with a t

79 Gram-negative bloodstream infections represent a significant

80 Gram-negative pathogens are enveloped by an outer membrane th

81 ility testing using a collection of 297 Gram-negative bacilli, including members of the order Enterob

82 vailable genome sequences of over 1,300 Gram-negative strains.

83 included): Gram-positive bacteria, 58%; Gram-negative bacteria, 78%; and Candida species, 83%.

84 he MICs of CFDC were determined for 610 Gram-negative bacilli, including 302 multinational Enterobact

85 Helicobacter pylori is a gram-negative bacterium that persistently colonizes the human

86 wn requirements for PIC targeting are a Gram-negative cell envelope and a unique cell surface antigen

87 Proteus mirabilis is a Gram-negative uropathogen and frequent cause of catheter-asso

88 d 0.5-17 years with community acquired, gram-negative quinolone-resistant bacteriuria.

89 ore cephalosporin with activity against Gram-negative bacterial species that are resistant to carbape

90 folding is an essential process in all Gram-negative bacteria, and considering the looming crisis of

91 Among Gram-negative bacteria, Escherichia coli were predominant.

92 ibit both gram-positive (S. aureus) and gram-negative (E. coli) bacteria on solid and porous surfaces

93 t Gram-positive (Bacillus subtilis) and Gram-negative (Escherichia coli) targets.

94 phylococcus aureus bacteremia (SAB) and gram-negative bacteremia (GNB) to compare the characteristics

95 ilters quickly killed Gram-positive and Gram-negative bacteria aerosols in vitro, with CFU reductions

96 Mitochondria, chloroplasts and Gram-negative bacteria are encased in a double layer of membr

97 The proportion of Gram-positive and Gram-negative bacteria were 135(68.2%) and 63(31.8%) respecti

98 staphylococci, other gram-positive, and gram-negative bacteria, respectively.

99 for Gram-positive Bacillus subtilis and Gram-negative Escherichia coli as model organisms to monitor

100 were quantified in keratitis caused by Gram-negative bacteria.

101 80% of prostatitis cases are caused by Gram-negative uropathogenic Escherichia coli (UPEC) or Gram-p

102 ocol susceptibility results for certain Gram-negative bacilli.

103 Here, we show that the cytosolic Gram-negative bacterium Shigella flexneri stalls apoptosis by

104 HCT subjects were studied (7.5% develop gram-negative infection), with 4,768 fecal samples for analys

105 microbial resistance phenotypes, during Gram-negative bacterial infection and will advance our unders

106 al mice to more severe infection during Gram-negative sepsis.

107 lly efficacious therapy for fermenting, gram-negative bacteria in blood culture(s) if they were afebr

108 a high-throughput scRNA-seq method for Gram-negative and Gram-positive bacteria that can resolve het

109 0.0001)-with pronounced differences for Gram-negative bacteria and Candida species.

110 isoprenoid synthesis, is essential for Gram-negative bacteria, mycobacteria and apicomplexans(2,3).

111 For Gram-negative cultures, the Verigene result correlated with u

112 Lipopolysaccharide derived from Gram-negative bacteria is a potent activator of circulating i

113 ard understanding betaOMP biogenesis in Gram-negative bacteria and in mitochondria.

114 portant cell surface polysaccharides in gram-negative bacteria where they extend core lipopolysacchar

115 alent cause of antibiotic resistance in Gram-negative bacteria, i.e., the deactivation of the most wi

116 In Gram-negative bacteria, PG is assembled in the cytoplasm and

117 LPS transfection; however, its role in Gram-negative bacteria-mediated NLRP3 inflammasome activation

118 ion (RND) superfamily are ubiquitous in Gram-negative bacteria.

119 y antibiotic resistance determinants in Gram-negative bacteria.

120 Many Gram-negative bacterial pathogens interact with mammalian cel

121 Many gram-negative pathogens such as Neisseria meningitidis and Es

122 ivity against multidrug-resistant (MDR) Gram-negative pathogens as the pipeline of antibiotics is ess

123 monoderm) and those with two membranes (Gram-negative or diderm) is a fundamental open question in th

124 ibrio species and a set of monotrichous Gram-negative bacteria.

125 captures single-cell transcriptomes of Gram-negative and Gram-positive bacteria with high purity and

126 The outer membrane (OM) of gram-negative bacteria confers innate resistance to toxins an

127 The asymmetric outer membrane (OM) of Gram-negative bacteria functions as a selective permeability

128 The highly asymmetric outer membrane of Gram-negative bacteria functions in the defense against cytot

129 The cell envelope of Gram-negative bacteria is a multilayered structure essential

130 The outer membrane (OM) of Gram-negative bacteria is a selective permeability barrier th

131 The outer membrane (OM) of Gram-negative bacteria is an asymmetric lipid bilayer that co

132 Recent recurrent outbreaks of Gram-negative bacteria show the critical need to target essen

133 the decoration of the outer surface of gram-negative bacteria with proteins tethered to the outer me

134 ), a component of the outer membrane of gram-negative bacteria, disrupts the alveolar-capillary barri

135 brane is a key virulence determinant of gram-negative bacteria.

136 otropic effects on the functionality of gram-negative bacterial cell envelopes.

137 use our findings to propose a model of Gram-negative cell envelope stabilization that includes cell

138 study investigated the inactivation of Gram-negative Escherichia coli (E. coli) and Gram-positive En

139 rongly associated with lower numbers of Gram-negative organisms at indoor sites (p < 0.0001).

140 stain for delineating gram-positive or gram-negative bacteria or fungi within corneal scrapes.

141 nce genes, and both Pan Candida and Pan Gram-Negative targets that are unique to the BCID-GP Panel.

142 tant (XDR) and pan-drug-resistant (PDR) Gram-negative pathogens.

143 nfections caused by multidrug-resistant Gram-negative bacteria.

144 Multidrug resistant Gram-negative bacterial infections are an increasing public h

145 stic and frequently multidrug-resistant Gram-negative bacterial pathogen that primarily infects criti

146 Treatment of multidrug-resistant Gram-negative bacterial pathogens represents a critical clini

147 including against carbapenem-resistant gram-negative pathogens.

148 prokaryotes, and in particular, several Gram-negative bacterial pathogens including Neisseria meningi

149 eered to attach specifically to several Gram-negative organisms, including the human pathogens Escher

150 re covalently attached to PG in several Gram-negative species, including Coxiella burnetii, Agrobacte

151 id not suspect that slow-growing, small Gram-negative bacteria might be harmful.

152 Not surprisingly, Gram-negative bacteria have evolved diverse posttranslational

153 cacy against Gram-positive strains than Gram-negative ones.

154 The Gram-negative anaerobe, Porphyromonas gingivalis, is a key pe

155 regate lipopolysaccharide (LPS) and the Gram-negative bacterium Escherichia coli However, the physiol

156 In the Gram-negative bacterium Escherichia coli, membrane-bound sens

157 s spanning different classes within the Gram-negative phylum Proteobacteria: Agrobacterium tumefacien

158 The Gram-negative Shigella species are close relatives of Escheri

159 In the Gram-negative social bacterium, Myxococcus xanthus, a putativ

160 MN riboswitch binders against wild-type Gram-negative bacteria.

161 nstrate label-free readout on unlabeled Gram-negative and Gram-positive species.

162 rial including adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary care h

163 stion "Does transitioning patients with gram-negative bloodstream infections from intravenous to oral

164 pared to the cell-grown vaccine but the H3N2-negative population had significantly greater titers to

165 gration of intrahepatic HBV DNA in the HBeAg-negative stage may be higher than previously anticipated

166 (HCV)-viremic heart transplantation into HCV-negative recipients with HCV treatment are good.

167 lantation of 30 HCV-viremic kidneys into HCV-negative recipients, followed by early initiation of an

168 Compared to accepting only HCV-negative hearts, accepting any heart gained 0.14 life-ye

169 Only HIV-negative or HCV-negative participants not on medication assisted treatme

170 an epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer represents a major mil

171 an epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who had received <=2 c

172 an epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer with prior clinical be

173 lly or cytologically confirmed advanced HER2-negative breast cancer, an Eastern Cooperative Oncology

174 iscrimination between HER2-positive and HER2-negative tumors as early as 2 h after injection (tumor-t

175 ssociated with poor clinical outcome in HER2-negative GC.

176 Premenopausal women with HR-positive/HER2-negative breast cancer and high recurrence risk, as defi

177 Overall, 202 untreated patients with HER2-negative AEGC and a Zubrod performance status of 0-1 wer

178 HER2-positive metastases in women with HER2-negative primary breast cancer.

179 HER2-positive metastases in women with HER2-negative primary breast cancer.

180 from 1802 human immunodeficiency virus (HIV)-negative children aged 1-59 months enrolled in the Pneum

181 ospective human immunodeficiency virus (HIV)-negative UK cohort of 333 tuberculosis contacts.

182 HIV-negative, non-pregnant Rwandan BV patients were randomiz

183 Of 3259 HIV-negative MSM, 19% were currently using PrEP, 6% had used

184 In a new UK cohort of 333 HIV-negative tuberculosis contacts with a median follow-up o

185 In 368 HIV-negative MSM and 72 HIV-negative MSW T-lymphocyte phenot

186 l load) were virally suppressed, and 673 HIV-negative men (40% of 1673) were circumcised in intervent

187 In 368 HIV-negative MSM and 72 HIV-negative MSW T-lymphocyte phenotyping was performed 3 ti

188 ed 3 rapid urine tests in 372 ambulatory HIV-negative individuals suspected of having TB in South Afr

189 similar effect size, in both the PWH and HIV-negative (P <= .05 for all).

190 ype IV-B, was the most prevalent in both HIV-negative (38% at baseline, 30% at the follow-up visit) a

191 mong 598 HIV-positive and 550 comparable HIV-negative participants aged >= 45 years of the AGEhIV Coh

192 In both high- and low-income countries, HIV-negative children born to HIV-positive mothers (HIV expo

193 ch therapy with dolutegravir in healthy, HIV-negative adults was halted early after two of the four p

194 s are required to match drug exposure in HIV-negative patients.Conclusions: Weight-based dosing of ri

195 %, led to specificities of 91.3-95.3% in HIV-negative women and 77.0-85.8% in HIV-positive women.

196 iated with persistent hrHPV infection in HIV-negative women but not in HIV-positive women.

197 ithelial neoplasia grade 2 or greater in HIV-negative women using manufacturer-defined cycle threshol

198 In HIV-negative women, women with Lactobacillus dominant microb

199 idence interval, 1.59-1.67) and those in HIV-negative women.

200 - and socioeconomic status (SES)-matched HIV-negative controls (HIV-).

201 CD4 T cells from the blood and rectum of HIV-negative (HIV(-)) and antiretroviral therapy (ART)-suppr

202 ith viral suppression; and proportion of HIV-negative men circumcised.

203 Only HIV-negative or HCV-negative participants not on medication

204 Consecutive PLWH (n = 169) and at-risk HIV-negative individuals (n = 126) were recruited from 2 US

205 with anal precancer in HIV+ and at-risk HIV-negative women from the Atlanta Women's Interagency HIV

206 nal cancer screening in HIV+ and at-risk HIV-negative women.

207 eople known to be HIV-positive or tested HIV-negative in the preceding 12 months; proportion of peopl

208 or guardian, and individuals who tested HIV-negative within the past 3 months but who reported a rec

209 nce interval [CI], -2.8 to .1) less than HIV-negative individuals during the first 2 months of tuberc

210 units lower on the OCS-Plus measure than HIV-negative participants.

211 women aged 30-65 years, 586 of whom were HIV-negative and 535 HIV-positive.

212 partnerships where both individuals were HIV-negative, we compared observed concordance in preexposur

213 Surprisingly, among HPV-negative cases, a gene signature for HPV status was pred

214 in tumor regression in HPV-positive and HPV-negative HNSCC PDXs.

215 Thus, HNSCC can be separated into HPV-negative and HPV-positive HNSCC.

216 However, in this largely MHC-class-I-negative tumor, the mechanism of action of anti-PD-1 the

217 cell (PBMC) analysis on a subgroup of 26 IgG-negative participants.

218 PBMCs were collected from 23/26 EBOV IgG-negative participants.

219 ut compared to converters, persistently IGRA-negative contacts produced more proinflammatory cytokine

220 In histology/image-negative disease, elevated NETest may reflect early evid

221 even cohorts of patients with different INI1-negative solid tumours or synovial sarcoma.

222 CI, 82% to 94%), with iPET-positive and iPET-negative patients having similar outcomes.

223 a CD30-positive, anaplastic lymphoma kinase-negative T-cell lymphoma.

224 Mothers of KSHV-negative children had higher geometric mean titers than

225 r in PD-L1-positive (8/28; 29%) versus PD-L1-negative (0/12; 0%) patients.

226 ses in Locus for Enterocyte Effacement (LEE)-negative STEC infection.

227 plays a crucial role in the survival of LEE-negative STEC as well as inducing apoptosis of the host

228 one marrow, CSF1R-FRed was absent in lineage-negative hematopoietic stem cells, arguing against a dir

229 cultured erythroid progenitor cells from MAM-negative individuals show markedly increased proliferati

230 opoietic cells of all humans except rare MAM-negative individuals.

231 ional output owing to disruption of the MDM2-negative feedback loop.

232 ere 72% and 84% for ITT, 85% and 91% for MRD-negative patients, and 57% and 72% for patients with hig

233 had no effect in either MRD-positive or MRD-negative patients.

234 afe nonoperative surveillance for >80% of MT-negative patients.

235 0; and 155 (25%) participants who tested MTB-negative had scores >70.

236 Because of this asymmetry, the net-negative charge at the inner leaflet exceeds that at the

237 hing sample, this benefit persisted for node-negative women (HR 0.80 [95% CI 0.66-0.97]; p=0.007), no

238 Non-negative matrix factorization identified 3 HFpEF transcr

239 deconvolution analysis by implementing a non-negative linear least-squares fitting algorithm in conju

240 mpared to principal components analysis, non-negative matrix factorization or no DR.

241 nalysis, independent component analysis, non-negative matrix factorization, t-distributed stochastic

242 A valid dwell time solution should be non-negative and duplicate the shape of the desired removal

243 The non-negative linear least-squares method yields the best res

244 fragmentation patterns via unsupervised non-negative matrix factorization and quantifies the reprodu

245 mtDNA depletion and cytochrome c oxidase-negative cells were found ex vivo in biopsies of affecte

246 itor pevonedistat decreased growth of Rb/p53-negative patient-derived cell lines and mouse xenografts

247 64 pandemic-era samples from SARS-CoV-2 PCR-negative patients with respiratory symptoms.

248 case series of 12 patients with culture/PCR-negative body fluids but for whom an infectious diagnosi

249 native viral infections in SARS-CoV-2 RT-PCR-negative PUIs (n = 30) and viral coinfections in SARS-Co

250 TP-binding cassette (ABC) transporter in PEL-negative individuals.

251 Interestingly, PEL-negative individuals showed an impaired platelet aggrega

252 PET scans (n = 103), the 5-year TTP for PET-negative cases by Deauville criteria (D1-D3, DX) was 91%

253 Patients with Philadelphia-negative myeloproliferative neoplasm (MPN) are prone to

254 were identified (1 patient changed from PSMA-negative to PSMA-positive).

255 H pylori-negative status had a beneficial effect on the score ove

256 LB as case study, we monitored healthy (qPCR-negative) in-field grown citrus trees and compared their

257 atistical analysis, we also showed that qPCR-negative plants exhibited HLB-specific spectral characte

258 out mice, and receptor-positive and receptor-negative intercalated cells from the same knockout mice.

259 ecimen was spiked into pooled SARS-CoV-2 RNA-negative specimen remnants for the various medium types.

260 Virulence inhibitory activity in the RND-negative background resulted from OmpR repression of the

261 Compared to RSV-negative ARI cases, RSV-positive cases were associated w

262 ion, indicating an exhausted status of SATB1-negative malignant T cells.

263 y cases, the etiology is unknown in most SRY-negative patients.

264 (S. stercoralis-positive and S. stercoralis-negative respectively).

265 connectivity between task-positive and task-negative networks in pediatric OCD may contribute to the

266 ll, binding across both tau-positive and tau-negative non-Alzheimer disorders did not reliably corres

267 take in these regions compared to young, tau-negative controls.

268 We conducted a test-negative study of influenza VE in community-dwelling old

269 In the test-negative design, routine testing at health-care faciliti

270 ps in comparisons of toxin-positive to toxin-negative patients.

271 Triple-negative breast cancer (TNBC) constitutes 10 to 15% of a

272 Triple-negative breast cancer (TNBC) is among the most aggressi

273 Triple-negative breast cancer (TNBC) is characterized by its ag

274 Triple-negative breast cancer (TNBC), representing ~15% of glob

275 hibition of HS cleavage in MDA-MB-231 triple-negative breast cancer (TNBC) cells.

276 all derived from parental MDA-MB-231 triple-negative breast cancer cells.

277 majority of which display aggressive triple-negative IC10 gene activity.

278 5.63 and 3.02 for luminal A-like and triple-negative disease, respectively.

279 or 3 (HER3) have been investigated as triple-negative breast cancer (TNBC) biomarkers.

280 et assays indicated that 8a decreases triple-negative breast cancer cell viability, and immunoblottin

281 ma (T98G) and a high ABCB1 expressing triple-negative breast cancer cell line (MDA-MB-231-luc) were t

282 y stage bone and lung metastasis from triple-negative breast cancer that should be given prior to con

283 iety of cancer cells, including human triple-negative breast cancer (TNBC) and patient-derived TNBC c

284 In triple-negative breast cancer (TNBC), miR-127 downregulation co

285 aftment and lung metastatic growth in triple-negative breast cancer (TNBC).

286 specific to tumor-initiating cells in triple-negative breast cancer xenografts that rely on LEFTY1 fo

287 ly recurrent inoperable or metastatic triple-negative breast cancer using a block method (block size

288 motherapy in patients with metastatic triple-negative breast cancer.

289 Using models of triple-negative breast cancer (TNBC) with different intratumora

290 Studies of triple-negative breast cancer (TNBC)-a highly aggressive malign

291 maintain the mesenchymal phenotype of triple-negative breast cancer cells and that CBFbeta-depleted c

292 growth and spontaneous metastasis of triple-negative breast cancer.

293 OTULIN or Wnt/beta-catenin sensitizes triple-negative breast cancer xenograft tumors to chemotherapeu

294 f ZEB1 in basal-like tumor cells, two triple-negative breast cancer (TNBC) subtypes, to demonstrate t

295 roved prospective study, a woman with triple-negative breast cancer (age, 49 years) underwent (13)C M

296 Treatment of patients with triple-negative breast cancer (TNBC) is limited by a lack of ef

297 sitive for cancer; and 264 patients had true-negative findings based on follow-up imaging for a minim

298 tached vitreous at the time of surgery (true-negative results), and 8 eyes had pre-existing PVD at th

299 ) and high (25%) Ct tertiles and Xpert Ultra-negative (30%) probable TBM cases (p=.01).

300 pattern (TH-positive, DAT-negative, ZsGreen-negative) was found in A12-A13.